Sotuletinib (formerly BLZ945; BLZ-945) is a novel, potent, selective, orally bioactive, and brain-penetrant CSF-1R (colony stimulating factor 1 receptor) inhibitor with potential antitumor activity.

Sulfatinib, formerly known as surufatinib, is an orally bioavailable, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3, and the fibroblast growth factor receptor type 1 (FGFR1), with potential antineoplastic and anti-angiogenic activities.

GW2580 (also known as SC-203877) is a novel, potent, selective, and orally bioavailable c-Fms kinase CSF-1R inhibitor with potential antineoplastic activity.

PLX5622 is a novel and highly selective CNS-penetrant CSF1R inhibitor, that has the potential to be used for extended and specific microglial elimination, preceding and during pathology development.